Association between methamphetamine versus amphetamine and acute psychiatric symptoms

Journal of Dual Diagnosis

Volumn 9, Issue 4, 2013, Pages 292-300

  Medhus, Sigrid ^a,b   Holm, Bjørn ^a   Mørland, Jørg ^b,c   Bramness, Jørgen G ^b,c  

^a LOVISENBERG DIAKONALE HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

methamphetamine; psychopathology; psychoses; psychostimulants

Indexed keywords

ALCOHOL; ALPRAZOLAM; AMPHETAMINE; CANNABIS; CLONAZEPAM; CODEINE; DIAZEPAM; ETHYLMORPHINE; FLUNITRAZEPAM; METHADONE; METHAMPHETAMINE; MORPHINE; NITRAZEPAM; NORDAZEPAM; OXAZEPAM; ZOLPIDEM; ZOPICLONE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRIVER; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; MENTAL DISEASE; PSYCHIATRIC DEPARTMENT;

EID: 84887835972     PISSN: 15504263     EISSN: 15504271     Source Type: Journal    
DOI: 10.1080/15504263.2013.835161     Document Type: Article

References (48)

1. Balster, R. L., & Schuster, C. R. (1973). A comparison of d-amphetamine, l-amphetamine, and methamphetamine self-administration in rhesus monkeys. Pharmacogy Biochemistry and Behaviour, 1(1), 67-71.
2. Baselt, R. (2011). Disposition of toxic drugs and chemicals in man. Foster City, CA: Biomedical Publications.
3. Bell, D. S. (1973). The experimental reproduction of amphetamine psychosis. Archives of General Psychiatry, 29(1), 35-40.
4. Bogstrand, S. T., Middelkoop, G., & Christophersen, A. S. (2011). Trends in amphetamine and benzodiazepine use among drivers arrested for drug impaired driving in Norway 2000-2009. Norsk Epidemiologi, 21(1), 61-66.
5. Bramness, J. G., Skurtveit, S., & Morland, J. (2002). Clinical impairment of benzodiazepines-relation between benzodiazepine concentrations and impairment in apprehended drivers. Drug and Alcohol Dependence, 68(2), 131-141. doi:10.1016/S0376-8716(02)00188-6
6. Caton, C. L., Drake, R. E., Hasin, D. S., Dominguez, B., Shrout, P. E., Samet, S., & Schanzer, B. (2005). Differences between earlyphase primary psychotic disorders with concurrent substance use and substance-induced psychoses. Archives of General Psychiatry, 62, 137-145. doi:10.1001/archpsyc.62. 2.137
7. Caton, C. L., Hasin, D. S., Shrout, P. E., Drake, R. E., Dominguez, B., First, M. B., & Schanzer, B. (2007). Stability of early-phase primary psychotic disorders with concurrent substance use and substance-induced psychosis. British Journal of Psychiatry, 190, 105-111. doi:10.1192/bjp.bp.105. 015784
8. Chen, C. K., Lin, S. K., Sham, P. C., Ball, D., Loh, E. W., Hsiao, C. C., . . . Murray, R. M. (2003). Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis. Psychological Medicine, 33, 1407-1414.
9. Chen, C. K., Lin, S. K., Sham, P. C., Ball, D., Loh, E. W., & Murray, R. M. (2005). Morbid risk for psychiatric disorder among the relatives of methamphetamine users with and without psychosis. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 136B, 87-91. doi:10.1002/ajmg.b. 30187
10. Christophersen, A. S., &Morland, J. (1997). Drugged driving, a review based on the experience in Norway. Drug and Alcohol Dependence, 47(2), 125-135. doi:10.1016/S0376-8716(97)00081-1
11. de la Torre, R., Farre, M., Navarro, M., Pacifici, R., Zuccaro, P., & Pichini, S. (2004). Clinical pharmacokinetics of amphethamine and related substances: Monitoring in conventional and non-conventional matrices. Clinical Pharmacokinetics, 43(3), 157-185. doi:10.2165/00003088-200443030-00002
12. Degenhardt, L., Roxburgh, A., Black, E., Bruno, R., Campbell, G., Kinner, S. & Fetherstone, J. (2008). The epidemiology of methamphetamine use and harm in Australia. Drug and Alcohol Review, 27(3), 243-252. doi:10.1080/ 09595230801950572
13. Degenhardt, L., Roxburgh, A.,&McKetin, R. (2007). Hospital separations for cannabis-and methamphetamine-related psychotic episodes in Australia. The Medical Journal of Australia, 186(7), 342-345.
14. Durell, T. M., Kroutil, L. A., Crits-Christoph, P., Barchha, N., & Van Brunt, D. L. (2008). Prevalence of nonmedical methamphetamine use in the United States. Substance Abuse Treatment, Prevention, and Policy, 3, 19. doi:10.1186/1747-597X-3-19
15. European Monitoring Center for Drugs and Drug Addiction. (2009a). 2009
16. National report (2008 data) to the EMCDDA. Norway. New developments, trends and in-depth imformation on selected issues. Luxembourg: Office for Official Publications of the European Communities.
17. European Monitoring Center for Drugs and Drug Addiction. (2009b). Metamphetamine. A European Union perspective in the global context. Luxembourg: Office for Official Publications of the European Communities.
18. European Monitoring Center for Drugs and Drug Addiction. (2010). Problem amphetamine and methamphetamine use in Europe. Luxembourg: Office for Official Publications of the European Communities.
19. European Monitoring Center for Drugs and Drug Addiction. (2011). Amphetamine. A European Union perspective in the global context. Luxembourg: Office for Official Publications of the European Communities.
20. Flesland, L., & Carlsen, S. (2010). Fre var. Rustrender i Bergen. Bergen, Norway: Stiftelsen Bergenklinikkene.
21. Gonzales, R., Ang, A., McCann, M. J., & Rawson, R. A. (2008). An emerging problem: Methamphetamine abuse among treatment seeking youth. Substance Abuse, 29(2), 71-80. doi:10.1080/08897070802093312
22. Grelotti, D. J., Kanayama, G., & Pope, H. G., Jr. (2010). Remission of persistentmethamphetamine-induced psychosis after electroconvulsive therapy: Presentation of a case and review of the literature. American Journal of Psychiatry, 167, 17-23. doi:10.1176/appi.ajp.2009.08111695
23. Hall, D. A., Stanis, J. J., Marquez, A. H., & Gulley, J. M. (2008). A comparison of amphetamine-and methamphetamine-induced locomotor activity in rats: Evidence for qualitative differences in behavior. Psychopharmacology, 195(4), 469-478. doi:10.1007/s00213-007-0923-8
24. Hall,W., Hando, J., Darke, S., & Ross, J. (1996). Psychological morbidity and route of administration among amphetamine users in Sydney, Australia. Addiction, 91, 81-87.
25. Harris, D., & Batki, S. L. (2000). Stimulant psychosis: Symptom profile and acute clinical course. American Journal on Addictions, 9, 28-37.
26. Jonsson, L. E., & Sjostrom, K. (1970). A rating scale for evaluation of the clinical course and symptomatology in amphetamine psychosis. British Journal of Psychiatry, 117(541), 661-665.
27. Katz, G., Durst, R., Shufman, E., Bar-Hamburger, R., & Grunhaus, L. (2008). Substance abuse in hospitalized psychiatric patients. The Israel Medical Association Journal, 10(10), 672-675.
28. Kirkpatrick,M. G., Gunderson, E.W., Johanson, C. E., Levin, F. R., Foltin, R. W., & Hart, C. L. (2011). Comparison of intranasal methamphetamine and d-amphetamine self-administration by humans. Addiction, 107, 783-791. doi:10.1111/j.1360-0443.2011.03706.x
29. Kittirattanapaiboon, P., Mahatnirunkul, S., Booncharoen, H., Thummawomg, P., Dumrongchai, U., & Chutha, W. (2010). Long-term outcomes in methamphetamine psychosis patients after first hospitalisation. Drug and Alcohol Review, 29, 456-461. doi:1465-3362.2010.00196.x
30. Kripos (National Crime Investigation Service). (2012). Narkotika-og dopingstatistikk 2011 [Narcotics and doping statistics 2011]. Oslo, Norway: KRIPOS. Retrieved from https://www.politi.no/vedlegg/lokale vedlegg/kripos/ Vedlegg 1580.pdf
31. Kuczenski, R., Segal, D. S., Cho, A. K., & Melega, W. (1995). Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine. The Journal of Neuroscience, 15(2), 1308-1317.
32. Kuhn, D. M., Appel, J. B., & Greenberg, I. (1974). An analysis of some discriminative properties of d-amphetamine. Psychopharmacologia, 39(1), 57-66.
33. Lamb, R. J., & Henningfield, J. E. (1994). Human d-amphetamine drug discrimination: Methamphetamine and hydromorphone. Journal of the Experimental Analysis of Behaviour, 61(2), 169-180. doi:10.1901/jeab.1994.61-169
34. Leamon, M. H., Flower, K., Salo, R. E., Nordahl, T. E., Kranzler, H. R., & Galloway, G. P. (2010). Methamphetamine and paranoia: The methamphetamine experience questionnaire. American Journal on Addictions, 19, 155-168. doi:1521-0391.2009.00014.x
35. Mathias, S., Lubman, D. I., & Hides, L. (2008). Substance-induced psychosis: A diagnostic conundrum. Journal of Clinical Psychiatry, 69(3), 358-367. doi:10.4088/JCP.v69n0304
36. Maxwell, J. C., & Rutkowski, B. A. (2008). The prevalence of methamphetamine and amphetamine abuse in North America: A review of the indicators, 1992-2007. Drug and Alcohol Review, 27(3), 229-235. doi:10.1080/09595230801919460
37. McGregor, C., Srisurapanont, M., Jittiwutikarn, J., Laobhripatr, S., Wongtan, T.,&White, J. M. (2005). The nature, time course and severity of methamphetamine withdrawal. Addiction, 100(9), 1320-1329. doi:10.1111/j.1360- 0443.2005.01160.x
38. McKetin, R., Kozel, N., Douglas, J., Ali, R., Vicknasingam, B., Lund, J., & Li, J. H. (2008). The rise of methamphetamine in Southeast and East Asia. Drug and Alcohol Review, 27(3), 220-228. doi:10.1080/09595230801923710
39. McKetin, R., McLaren, J., Lubman, D. I., & Hides, L. (2006). The prevalence of psychotic symptoms among methamphetamine users. Addiction, 101(10), 1473-1478. doi:10.1111/j.1360-0443.2006.01496.x
40. Mendelson, J., Uemura, N., Harris, D., Nath, R. P., Fernandez, E., Jacob, P., . . . Jones, R. T. (2006). Human pharmacology of the methamphetamine stereoisomers. Clinical Pharmacology & Therapeutics, 80(4), 403-420. doi:10.1016/j.clpt.2006.06.013
41. Mordal, J., Bramness, J. G., Holm, B., & Morland, J. (2008). Drugs of abuse among acute psychiatric and medical admissions: Laboratory based identification of prevalence and drug influence. General Hospital Psychiatry, 30(1), 55-60. doi:10.1016/j.genhosppsych.2007.10.006
42. Segal, D. S., & Kuczenski, R. (1997). Repeated binge exposures to amphetamine and methamphetamine: Behavioral and neurochemical characterization. The Journal of Pharmacology and Experimental Therapeutics, 282(2), 561-573.
43. Shoblock, J. R., Sullivan, E. B., Maisonneuve, I. M., & Glick, S. D. (2003). Neurochemical and behavioral differences between d-methamphetamine and d-amphetamine in rats. Psychopharmacology, 165(4), 359-369. doi:10.1007/s00213- 002-1288-7
44. Srisurapanont, M., Ali, R., Marsden, J., Sunga, A., Wada, K., & Monteiro, M. (2003). Psychotic symptoms in methamphetamine psychotic in-patients. International Journal of Neuropsychopharmachology, 6, 347-352. doi:10.1017/S1461145703003675
45. Srisurapanont, M., Arunpongpaisal, S., Wada, K., Marsden, J., Ali, R., & Kongsakon, R. (2011). Comparisons of methamphetamine psychotic and schizophrenic symptoms: A differential item functioning analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 35, 959-964. doi:10.1016/j.pnpbp.2011.01.014
46. Ujike, H., Katsu, T., Okahisa, Y., Takaki, M., Kodama, M., Inada, T., . . . Kuroda, S. (2009). Genetic variants of D2 but not D3 or D4 dopamine receptor gene are associated with rapid onset and poor prognosis of methamphetamine psychosis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 33, 625-629. doi:10.1016/j.pnpbp.2009.02.019
47. Williamson, S., Gossop, M., Powis, B., Griffiths, P., Fountain, J., & Strang, J. (1997). Adverse effects of stimulant drugs in a community sample of drug users. Drug and Alcohol Dependence, 44(2-3), 87-94. doi:10.1016/S0376- 8716(96)01324-5
48. Yokel, R. A., & Pickens, R. (1973). Self-administration of optical isomers of amphetamine and methylamphetamine by rats. The Journal of Pharmacology and Experimental Therapeutics, 187(1), 27-33.